Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Healthy Volunteers

DMT for Healthy Volunteers

45 papers and 17 clinical trials exploring dmt as a treatment for healthy volunteers.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

45 papers
Open Accessmeta

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects

This systematic review (s=32) of healthy adult volunteers examined the pharmacokinetics of LSD, psilocybin, DMT, mescaline and 5-MeO-DMT. It found that LSD and psilocybin showed dose-related peak levels, while oral and intravenous DMT differed in ways that may matter clinically.

Published
May 29, 2026
Journal
Journal of Psychopharmacology
Authors
Hampsey, E., Martin, K., Kalfas, M., Benson, L., Wihlborg, S., Jelen, L., Young, A. H., Rucker, J.
Open Accessindividual

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality

This randomised, placebo-controlled, double-blind crossover study (n=25) found that DMT (60 mg) increased psychotic-like experiences and suggestibility in healthy volunteers, alongside strong mystical and other psychedelic effects. The links between these effects appeared to be driven more by positive emotionality than by mystical experience alone.

Published
May 20, 2026
Journal
Research Square
Authors
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Medina, M., Mograbi, D., Coelho, N. G., Palhano-Fontes, F., Araujo, D.
Paywallindividual

5-HT1A receptor blockade potentiates the subjective effects of DMT

This double-blind, randomised, placebo-controlled within-subjects study (n=12) found that blocking the 5-HT1A receptor with 30 mg oral pindolol before a sub-hallucinogenic intravenous dose of DMT (7 mg/70kg) intensified the subjective effects with a moderate effect size, suggesting the 5-HT1A receptor contributes to how psychedelics produce their subjective effects.

Published
May 2, 2026
Journal
Journal of Psychopharmacology
Authors
Zahid, Z., Strassman, R. J., Qualls, C. R., Nayak, S. M.
Open Accessindividual

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

This psychometric analysis using the PES100 examined 816 measurements from healthy participants (n=386) across 15 controlled psychedelic studies of LSD, psilocybin, mescaline and DMT. It found that mystical oneness was strongly linked to feelings of luminous light and renewal, and moderately to strongly linked to ego disintegration, with these links increasing with dose.

Published
March 31, 2026
Journal
Religion, Brain & Behavior
Authors
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W., Sepeda, N. D., Straumann, I., Klaiber, A., Vogt, S. B., Erne, L., Ley, L., Becker, A. M., Vizeli, P., Holze, F., Liechti, M. E.
Open Accessindividual

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

This double-blind, randomised, placebo-controlled crossover study and separate open-label dose-escalation study (n=36) in healthy participants examined intravenous DMT and found that it produced very strong but short-lived subjective effects, peaking within 2 minutes and fading within 12 to 30 minutes. The strongest effects levelled off at 15 mg, and dose escalation appeared to improve tolerability compared with blinded dosing.

Published
March 27, 2026
Journal
Translational Psychiatry
Authors
Erne, L., Mueller, L., Straumann, I., Ademaj, B., Eckert, A., Vukalovic, I., Valenta, J., Luethi, D., Liechti, M. E., Vogt, S. B.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Clinical Trials

17 trials
Not yet recruitingPhase I

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

This Phase I, open-label, single-group trial (n=12) will study the pharmacokinetics, pharmacodynamics and safety of GH001 in healthy adults after a single inhaled dose delivered via a proprietary GH001 aerosol delivery system. The main purpose is to assess the serum pharmacokinetic profile of mebufotenin and the safety and tolerability of the treatment. All participants will receive a single inhaled dose of GH001 via an aerosol device. The study will measure serum mebufotenin PK parameters on Day 1, including Cmax, Tmax, terminal half-life, AUClast, AUCinf, partial area under the curve, terminal elimination rate constant, clearance, volume of distribution and Cmax/AUCinf. Safety will be assessed by the incidence of treatment-emergent adverse events through trial completion, with follow-up averaging about 3 weeks. Eligibility is limited to healthy adults aged 21 to 64 years with BMI 18.5 to 35 kg/m2 and normal spirometry.

Started
April 1, 2026
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07540494
RecruitingPhase I

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (LPD)

This randomised, placebo-controlled, triple-blind Phase I crossover trial (n=24) will compare the acute and subacute effects of LSD (150µg), psilocybin (30mg), and DMT (up to 2 mg/min intravenous infusion) in healthy adults, with all sessions standardised using ketanserin (20 mg IV) to end the psychedelic experience after three hours.

Started
April 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06899334
RecruitingPhase I

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans (DMT-Bolus)

This Phase I, randomised, placebo-controlled, triple-masked, crossover design trial (n=60) will investigate the safety, tolerability, electrophysiological effects, and efficacy of dimethyltryptamine (DMT) in individuals with major depressive disorder (MDD) and healthy controls.

Started
March 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06671977
RecruitingPhase I

Investigation of Psychedelic Effects in Psychoactive Substances

Triple-blind, placebo-controlled, within-subjects study (n=50) testing whether various psychoactive substances (psilocybin, ketamine, DXM, DMT, MDMA, THC) produce experiences similar to classic psychedelics across up to six single-dose sessions.

Started
February 5, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06772753
CompletedPhase I

Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

This randomised, triple-blind, placebo-controlled crossover trial (n=18) will investigate the acute analgesic (anti-pain) effects of N,N-dimethyltryptamine (DMT) on experimentally induced acute nociceptive pain, hyperalgesia, and allodynia in healthy participants.

Started
May 1, 2024
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06180759
CompletedPhase I

Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects (DHTP)

Randomised Phase I study (n=16) comparing PK/PD and safety of six varying doses of a fixed-combination of DMT and harmine across six study days in healthy volunteers with continuous psychological support.

Started
May 1, 2023
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT05829603

Explore further

Search all DMT papers Search all Healthy Volunteers trials Full DMT profile Full Healthy Volunteers profile